A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study

Trial Profile

A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Salmeterol (Primary)
  • Indications Subcutaneous fat disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Neothetics
  • Most Recent Events

    • 23 Mar 2017 Status changed from recruiting to discontinued, as reported in a Neothetics media release.
    • 02 Jul 2015 New trial record
    • 30 Jun 2015 According to a company media release, this is a supplemental safety study that Neothetics expects to submit to the US FDA as part of the company's NDA package for LIPO-202, which the company anticipates filing in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top